Latest studies
Every paper our editors flag with a plain-language note and an evidence rating. Filter by evidence, species, or design to find what actually applies to you.
- Study · BPC-157Weak / none
Efficient Expression of Small Molecule Bioactive Peptides in Bacillus licheniformis.
The novelty here is manufacturing rather than biology: a chromosomally integrated Bacillus expression system intended to make BPC 157 cheaper to produce at scale. The rat gastric-ulcer data are supportive but secondary, and the molecules given to animals were fusion constructs (GGT-BPC157 and mScarlet-BPC157), not free BPC 157, so the potency figures cannot be read across to the peptide sold under that name. There is no head-to-head comparison against synthetic peptide, no described blinding, and no human data.
Applied biochemistry and biotechnologyn=—AnimalAug 29, 2026 - Study · TB-500Mixed
Peptides in Regenerative Medicine: A Comprehensive Review of Clinical Applications in Tissue Repair and Chronic Pain Management.
A narrative review rather than new data, and the authors are explicit that the human evidence base for these peptides remains limited and largely preclinical. It is useful mainly as a map of proposed mechanisms and regulatory status for BPC-157, TB-500 and GHK-Cu in one place. Narrative reviews carry no systematic search or risk-of-bias assessment, so read the enthusiasm in the framing with that limit in mind. Regulatory status is unchanged: these remain unapproved for the indications discussed.
Current pain and headache reportsn=——Aug 24, 2026 - Study · TB-500Weak / none
Peptide Supplements and Their Therapeutic Applications in Sports Medicine.
This is the most direct literature audit yet of the peptides that dominate recovery marketing, and its finding is a familiar one: the animal work is interesting, the human work is thin. Sixty-seven percent of the included publications were preclinical, and the clinical studies that exist are heterogeneous in dose and route of administration. Worth citing on our BPC-157, TB-500, CJC-1295, ipamorelin and GHK-Cu pages as the current state of evidence, alongside the cardiovascular and metabolic risks the authors document.
The American journal of sports medicinen=——Aug 11, 2026 - Study · KisspeptinWeak / none
Rapid and harmonized analytical workflow for the determination of peptidic and non-peptidic doping agents in dried and liquid blood matrices.
This study is not a clinical or pharmacological investigation — it is a doping-control analytical methods paper, and should be read as such. Researchers developed and validated a streamlined workflow capable of detecting 54 prohibited substances, including BPC-157 and TB-500, across dried blood spots, serum, and plasma using a single microextraction step followed by liquid chromatography coupled with high-resolution mass spectrometry. The analytical performance was satisfactory by laboratory standards: detection limits ranged from 0.05–1.25 ng/mL, no carry-over was observed, and matrix effects were modest (5–33%). Notably, dried blood spot matrices preserved all compounds for the full study duration under non-refrigerated conditions — a meaningful practical advantage for anti-doping sample logistics. For readers tracking BPC-157 and TB-500 specifically: the stability data are striking. Both peptides showed complete degradation in serum within one week at room temperature or refrigerator temperature — a finding with direct implications for detection windows in anti-doping contexts. Dried matrices retained detectability throughout. This paper contributes nothing to the...
The Analystn=——Jun 22, 2026